Published in Curr Rheumatol Rep on July 01, 2014
Demographic and clinical features of inclusion body myositis in North America. Muscle Nerve (2015) 0.92
Ongoing developments in sporadic inclusion body myositis. Curr Rheumatol Rep (2014) 0.78
Physical impairment in patients with idiopathic inflammatory myopathies is associated with the American College of Rheumatology functional status measure. Clin Rheumatol (2014) 0.77
Mortality and Causes of Death in Patients with Sporadic Inclusion Body Myositis: Survey Study Based on the Clinical Experience of Specialists in Australia, Europe and the USA. J Neuromuscul Dis (2016) 0.75
Proposal for a Candidate Core Set of Fitness and Strength Tests for Patients with Childhood or Adult Idiopathic Inflammatory Myopathies. J Rheumatol (2015) 0.75
Invited Review: contractile activity-induced mitochondrial biogenesis in skeletal muscle. J Appl Physiol (1985) (2001) 3.35
Molecular and cellular adaptation of muscle in response to exercise: perspectives of various models. Physiol Rev (1991) 2.27
International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) (2003) 1.71
Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology (Oxford) (2002) 1.47
Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol (2001) 1.46
Inflammatory myopathies with mitochondrial pathology and protein aggregates. J Neurol Sci (2008) 1.28
Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis. Rheumatology (Oxford) (2008) 1.26
Long-term outcome in polymyositis and dermatomyositis. Ann Rheum Dis (2006) 1.22
Pathogenesis, classification and treatment of inflammatory myopathies. Nat Rev Rheumatol (2011) 1.18
Resistance and aerobic training in older men: effects on VO2peak and the capillary supply to skeletal muscle. J Appl Physiol (1985) (1997) 1.16
Skeletal muscle: energy metabolism, fiber types, fatigue and adaptability. Exp Cell Res (2010) 1.09
Effect of physical training on the proportion of slow-twitch type I muscle fibers, a novel nonimmune-mediated mechanism for muscle impairment in polymyositis or dermatomyositis. Arthritis Rheum (2007) 1.08
Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol (2005) 1.07
Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis. Rheumatology (Oxford) (2011) 1.05
Functional outcome and quality of life in adult patients with idiopathic inflammatory myositis. Rheumatology (Oxford) (2004) 1.05
Polymyositis with cytochrome oxidase negative muscle fibres. Early quadriceps weakness and poor response to immunosuppressive therapy. Brain (1997) 1.04
The possible role of physical exercise on the treatment of idiopathic inflammatory myopathies. Autoimmun Rev (2008) 1.01
Safety and efficacy of exercise training in patients with an idiopathic inflammatory myopathy--a systematic review. Rheumatology (Oxford) (2011) 0.98
Can muscle regeneration fail in chronic inflammation: a weakness in inflammatory myopathies? J Intern Med (2011) 0.97
Inclusion body myositis. Curr Neurol Neurosci Rep (2013) 0.95
Exercise as an anti-inflammatory intervention to combat inflammatory diseases of muscle. Curr Opin Rheumatol (2009) 0.94
Exercise as a therapeutic modality in patients with idiopathic inflammatory myopathies. Curr Opin Rheumatol (2012) 0.94
Vascular endothelial growth factor is highly expressed in muscle tissue of patients with polymyositis and patients with dermatomyositis. Arthritis Rheum (2008) 0.94
Endoplasmic reticulum stress in skeletal muscle homeostasis and disease. Curr Rheumatol Rep (2012) 0.94
Nonimmune mechanisms of muscle damage in myositis: role of the endoplasmic reticulum stress response and autophagy in the disease pathogenesis. Curr Opin Rheumatol (2009) 0.94
Longitudinal observational study of sporadic inclusion body myositis: implications for clinical trials. Neuromuscul Disord (2013) 0.94
The safety of a resistive home exercise program in patients with recent onset active polymyositis or dermatomyositis. Scand J Rheumatol (2000) 0.93
A longitudinal, integrated, clinical, histological and mRNA profiling study of resistance exercise in myositis. Mol Med (2010) 0.93
Treatment of the inflammatory myopathies: update and practical recommendations. Expert Opin Pharmacother (2009) 0.90
The effect of physical exercise following acute disease exacerbation in patients with dermato/polymyositis. Clin Rehabil (2003) 0.88
An update on pathogenic mechanisms of inflammatory myopathies. Curr Opin Rheumatol (2011) 0.88
New approaches to the assessment and treatment of the idiopathic inflammatory myopathies. Ann Rheum Dis (2012) 0.87
Mitochondrial pathology in immune and inflammatory myopathies. Curr Opin Rheumatol (2010) 0.87
Utility of magnetic resonance imaging in the evaluation of patients with inflammatory myopathies. Curr Rheumatol Rep (2001) 0.86
What determines quality of life in inclusion body myositis? J Neurol Neurosurg Psychiatry (2010) 0.86
Patients with polymyositis or dermatomyositis have reduced grip force and health-related quality of life in comparison with reference values: an observational study. Rheumatology (Oxford) (2010) 0.84
Exercise as a therapeutic tool to counteract inflammation and clinical symptoms in autoimmune rheumatic diseases. Autoimmun Rev (2012) 0.84
Intensive aerobic training improves motor performances and oxidative metabolism efficiency in chronic polymyositis: a case report. Neuromuscul Disord (2012) 0.84
Aerobic capacity in adult dermatomyositis/polymyositis patients and healthy controls. Arch Phys Med Rehabil (2000) 0.82
Improved exercise performance and increased aerobic capacity after endurance training of patients with stable polymyositis and dermatomyositis. Arthritis Res Ther (2013) 0.81
Intensive exercise and a patient in acute phase of polymyositis. J Back Musculoskelet Rehabil (2012) 0.80
Resistive exercise in the rehabilitation of polymyositis/dermatomyositis. J Rheumatol (1993) 0.80
Resistive home exercise in patients with recent-onset polymyositis and dermatomyositis -- a randomized controlled single-blinded study with a 2-year followup. J Rheumatol (2014) 0.80
Improvement in health and possible reduction in disease activity using endurance exercise in patients with established polymyositis and dermatomyositis: a multicenter randomized controlled trial with a 1-year open extension followup. Arthritis Care Res (Hoboken) (2013) 0.79
Glucocorticoid effects on skeletal muscle: benefit and risk in patients with autoimmune inflammatory rheumatoid diseases. Expert Rev Clin Immunol (2012) 0.78
Abnormal lactate levels in patients with polymyositis and dermatomyositis: the benefits of a specific rehabilitative program. Eur J Phys Rehabil Med (2013) 0.78
Exercise as an adjuvant treatment in persistent active polymyositis. J Clin Rheumatol (2014) 0.78
Limitations to the 6-minute walk test in dermatomyositis with interstitial lung disease in comparison with idiopathic interstitial pneumonia. Clin Med Insights Circ Respir Pulm Med (2013) 0.77
Biomarkers of inclusion body myositis. Curr Opin Rheumatol (2013) 0.77
Muscle metabolism in patients with polymyositis simultaneously evaluated by using 31P-magnetic resonance spectroscopy and near-infrared spectroscopy. Int J Clin Pract (2006) 0.76
Urinary levels of creatine and other metabolites in the assessment of polymyositis and dermatomyositis. Rheumatology (Oxford) (2003) 0.76
The physiology of inflammatory myopathies: an overview. Acta Physiol Scand (2001) 0.76
119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord (2004) 2.85
Patient perspectives on the impact of fibromyalgia. Patient Educ Couns (2008) 2.57
A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum (2004) 2.48
Identifying the clinical domains of fibromyalgia: contributions from clinician and patient Delphi exercises. Arthritis Rheum (2008) 2.22
Momentary relationship between cortisol secretion and symptoms in patients with fibromyalgia. Arthritis Rheum (2005) 1.98
Chronic widespread pain and fibromyalgia: what we know, and what we need to know. Best Pract Res Clin Rheumatol (2003) 1.94
Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum (2005) 1.89
Fibromyalgia syndrome module at OMERACT 9: domain construct. J Rheumatol (2009) 1.87
Self-regulatory deficits in fibromyalgia and temporomandibular disorders. Pain (2010) 1.68
Low serum levels of vitamin D in idiopathic inflammatory myopathies. Ann Rheum Dis (2012) 1.59
Fibromyalgia: where are we a decade after the American College of Rheumatology classification criteria were developed? Arthritis Rheum (2002) 1.58
Linking disease symptoms and subtypes with personalized systems-based phenotypes: a proof of concept study. Brain Behav Immun (2012) 1.53
Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies. J Clin Invest (2015) 1.51
Fibromyalgia syndrome. J Rheumatol (2005) 1.49
Leukocytes, cytokines, growth factors and hormones in human skeletal muscle and blood after uphill or downhill running. J Physiol (2004) 1.49
Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol (2002) 1.35
A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum (2007) 1.31
Predictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study. Arthritis Res Ther (2009) 1.29
International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials. Arthritis Rheum (2007) 1.28
High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood (2002) 1.26
Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med (2003) 1.25
Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum (2003) 1.20
Pathogenesis, classification and treatment of inflammatory myopathies. Nat Rev Rheumatol (2011) 1.18
Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum (2008) 1.18
Autoantibodies to cytosolic 5'-nucleotidase 1A in inclusion body myositis. Ann Neurol (2013) 1.16
T cell infiltrates in the muscles of patients with dermatomyositis and polymyositis are dominated by CD28null T cells. J Immunol (2009) 1.15
Sequential induction of pro- and anti-inflammatory prostaglandins and peroxisome proliferators-activated receptor-gamma during normal wound healing: a time course study. Prostaglandins Leukot Essent Fatty Acids (2007) 1.14
A symptom-based approach to pharmacologic management of fibromyalgia. Nat Rev Rheumatol (2009) 1.13
Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. Arthritis Rheum (2013) 1.12
Biology and therapy of fibromyalgia. Evidence-based biomarkers for fibromyalgia syndrome. Arthritis Res Ther (2008) 1.11
Potential roles of microsomal prostaglandin E synthase-1 in rheumatoid arthritis. Inflamm Regen (2011) 1.11
Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study. Arthritis Res Ther (2012) 1.11
Experiencing virtual patients in clinical learning: a phenomenological study. Adv Health Sci Educ Theory Pract (2011) 1.10
Pulmonary complications of polymyositis and dermatomyositis. Semin Respir Crit Care Med (2007) 1.10
Sleep stage dynamics in fibromyalgia patients and controls. Sleep Med (2008) 1.10
Effect of physical training on the proportion of slow-twitch type I muscle fibers, a novel nonimmune-mediated mechanism for muscle impairment in polymyositis or dermatomyositis. Arthritis Rheum (2007) 1.08
Reliability and validity of the myositis disease activity assessment tool. Arthritis Rheum (2008) 1.07
Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol (2005) 1.07
Down-regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids. Arthritis Rheum (2004) 1.06
Benefits of intensive resistance training in patients with chronic polymyositis or dermatomyositis. Arthritis Rheum (2007) 1.04
Effects of HMGB1 on in vitro responses of isolated muscle fibers and functional aspects in skeletal muscles of idiopathic inflammatory myopathies. FASEB J (2009) 1.04
Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay. Rheumatology (Oxford) (2010) 1.04
Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther (2013) 1.03
Functional index-2: Validity and reliability of a disease-specific measure of impairment in patients with polymyositis and dermatomyositis. Arthritis Rheum (2006) 1.01
The effect of anxiety and depression on improvements in pain in a randomized, controlled trial of pregabalin for treatment of fibromyalgia. Pain Med (2007) 1.00
Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome. J Rheumatol (2009) 0.99
Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature. Medicine (Baltimore) (2012) 0.99
Rheumatoid arthritis and salivary biomarkers of periodontal disease. J Clin Periodontol (2010) 0.98
Interstitial lung disease and idiopathic inflammatory myopathies: progress and pitfalls. Curr Opin Rheumatol (2010) 0.97
Expanded T cell receptor Vβ-restricted T cells from patients with sporadic inclusion body myositis are proinflammatory and cytotoxic CD28null T cells. Arthritis Rheum (2010) 0.97
Upregulation of MHC class I in transgenic mice results in reduced force-generating capacity in slow-twitch muscle. Muscle Nerve (2009) 0.96
Chronic opioid use in fibromyalgia syndrome: a clinical review. J Clin Rheumatol (2013) 0.96
Exercise as an anti-inflammatory intervention to combat inflammatory diseases of muscle. Curr Opin Rheumatol (2009) 0.94
Exercise as a therapeutic modality in patients with idiopathic inflammatory myopathies. Curr Opin Rheumatol (2012) 0.94
Vascular endothelial growth factor is highly expressed in muscle tissue of patients with polymyositis and patients with dermatomyositis. Arthritis Rheum (2008) 0.94
Association of the proinflammatory haplotype (MICA5.1/TNF2/TNFa2/DRB1*03) with polymyositis and dermatomyositis. Arthritis Rheum (2004) 0.94
Objective measures of disordered sleep in fibromyalgia. J Rheumatol (2009) 0.94
Endothelial cell activation and neovascularization are prominent in dermatomyositis. J Autoimmune Dis (2006) 0.93
Development of responder definitions for fibromyalgia clinical trials. Arthritis Rheum (2012) 0.93
A longitudinal, integrated, clinical, histological and mRNA profiling study of resistance exercise in myositis. Mol Med (2010) 0.93
Defective generation of a humoral immune response is associated with a reduced incidence and severity of collagen-induced arthritis in microsomal prostaglandin E synthase-1 null mice. J Immunol (2008) 0.92
Diclofenac delays micropore closure following microneedle treatment in human subjects. J Control Release (2012) 0.92
Impaired sleep quality in fibromyalgia: Detection and quantification with ECG-based cardiopulmonary coupling spectrograms. Sleep Med (2009) 0.92
Immune mechanisms in polymyositis and dermatomyositis and potential targets for therapy. Rheumatology (Oxford) (2013) 0.92
Microsomal prostaglandin E synthase-1: the inducible synthase for prostaglandin E2. Arthritis Res Ther (2005) 0.91
Toward development of a fibromyalgia responder index and disease activity score: OMERACT module update. J Rheumatol (2011) 0.91
Prostaglandin E2 differentially modulates proinflammatory/prodestructive effects of TNF-alpha on synovial fibroblasts via specific E prostanoid receptors/cAMP. J Immunol (2009) 0.91
Impaired myofibrillar function in the soleus muscle of mice with collagen-induced arthritis. Arthritis Rheum (2009) 0.91
Myeloid leukaemia in systemic lupus erythematosus--a nested case-control study based on Swedish registers. Rheumatology (Oxford) (2009) 0.91
Memory beliefs and function in fibromyalgia patients. J Psychosom Res (2005) 0.90
Microsomal prostaglandin E synthase-1 deficiency is associated with elevated peroxisome proliferator-activated receptor gamma: regulation by prostaglandin E2 via the phosphatidylinositol 3-kinase and Akt pathway. J Biol Chem (2006) 0.90
Immune mechanisms in the pathogenesis of idiopathic inflammatory myopathies. Arthritis Res Ther (2007) 0.90
Association of smoking and chronic pain syndromes in Kentucky women. J Pain (2011) 0.90
Sporadic inclusion body myositis: pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reaction. J Rehabil Med (2003) 0.90
Restricted T cell receptor BV gene usage in the lungs and muscles of patients with idiopathic inflammatory myopathies. Arthritis Rheum (2007) 0.89
The effects of pregabalin on sleep disturbance symptoms among individuals with fibromyalgia syndrome. Sleep Med (2009) 0.88
The role of TRAIL in mediating autophagy in myositis skeletal muscle: a potential nonimmune mechanism of muscle damage. Arthritis Rheum (2011) 0.87
TLR4 as receptor for HMGB1 induced muscle dysfunction in myositis. Ann Rheum Dis (2012) 0.87
Pathogenesis of idiopathic inflammatory myopathies. Curr Rheumatol Rep (2006) 0.87
Association of fibromyalgia with altered skeletal muscle characteristics which may contribute to postexertional fatigue in postmenopausal women. Arthritis Rheum (2013) 0.87
Creatine supplements in patients with idiopathic inflammatory myopathies who are clinically weak after conventional pharmacologic treatment: Six-month, double-blind, randomized, placebo-controlled trial. Arthritis Rheum (2007) 0.87
mPGES-1 null mice are resistant to bleomycin-induced skin fibrosis. Arthritis Res Ther (2011) 0.87
Implications of glucocorticoid therapy in idiopathic inflammatory myopathies. Nat Rev Rheumatol (2012) 0.87
Cytokines in idiopathic inflammatory myopathies. Autoimmunity (2006) 0.87
Controversies in COX-2 selective inhibition. J Rheumatol (2002) 0.86
Serial analysis of Ro/SSA and La/SSB antibody levels and correlation with clinical disease activity in patients with systemic lupus erythematosus. Scand J Rheumatol (2002) 0.86
The association of adverse pregnancy events and cardiovascular disease in women 50 years of age and older. J Womens Health (Larchmt) (2011) 0.86
Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine. Arthritis Res Ther (2012) 0.86
Prostaglandin E2 activates Rap1 via EP2/EP4 receptors and cAMP-signaling in rheumatoid synovial fibroblasts: involvement of Epac1 and PKA. Prostaglandins Other Lipid Mediat (2009) 0.86